Elixir Medical Announces Continued Excellent One Year Safety and Efficacy Data from the EXCELLA BD Randomized Clinical Trial for DESyne BD™ Novolimus Eluting Coronary Stent with Biodegradable Polymer

SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced one-year randomized clinical trial results today demonstrating the continued safety and efficacy of the Elixir DESyne™ BD Novolimus Eluting Coronary Stent System.